Loading clinical trials...
Loading clinical trials...
Multiple Consolidation Chemotherapy and DLI Prevent Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant and Achieving Complete Remission After Induction Chemotherapy and DLI
Conditions
Interventions
donor lymphocyte infusion
Locations
1
China
Peking University Institute of Hematology,Beijing
Beijing, Beijing Municipality, China
Start Date
March 1, 2017
Primary Completion Date
October 1, 2020
Completion Date
October 1, 2021
Last Updated
March 10, 2020
NCT07101588
NCT06093867
NCT04065399
NCT06859424
NCT07295951
NCT03970096
Lead Sponsor
Peking University People's Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions